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Brain responses to biological motion predict treatment
outcome in young children with autism
D Yang1,2, KA Pelphrey1, DG Sukhodolsky2, MJ Crowley2, E Dayan3, NC Dvornek2, A Venkataraman4, J Duncan5,6, L Staib5,6 and
P Ventola2
Autism spectrum disorders (ASDs) are common yet complex neurodevelopmental disorders, characterized by social,
communication and behavioral deficits. Behavioral interventions have shown favorable results—however, the promise of precision
medicine in ASD is hampered by a lack of sensitive, objective neurobiological markers (neurobiomarkers) to identify subgroups of
young children likely to respond to specific treatments. Such neurobiomarkers are essential because early childhood provides a
sensitive window of opportunity for intervention, while unsuccessful intervention is costly to children, families and society. In young
children with ASD, we show that functional magnetic resonance imaging-based stratification neurobiomarkers accurately predict
responses to an evidence-based behavioral treatment—pivotal response treatment. Neural predictors were identified in the
pretreatment levels of activity in response to biological vs scrambled motion in the neural circuits that support social information
processing (superior temporal sulcus, fusiform gyrus, amygdala, inferior parietal cortex and superior parietal lobule) and social
motivation/reward (orbitofrontal cortex, insula, putamen, pallidum and ventral striatum). The predictive value of our findings for
individual children with ASD was supported by a multivariate pattern analysis with cross validation. Predicting who will respond to
a particular treatment for ASD, we believe the current findings mark the very first evidence of prediction/stratification biomarkers in
young children with ASD. The implications of the findings are far reaching and should greatly accelerate progress toward more
precise and effective treatments for core deficits in ASD.
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INTRODUCTION
Within autism spectrum disorders (ASDs), core social communica-
tion symptoms are key targets for the development of pharma-
cological and behavioral interventions.1 Recent clinical trials of
behavioral interventions report favorable results.2–4 Yet, the
promise of targeted, precision medicine5 for core social commu-
nication deficits in ASD is hindered by a fundamental problem: the
lack of sensitive, objective markers to identify subgroups of young
children more or less likely to respond to specific treatments. By
objectively measuring brain responses, functional neuroimaging
techniques provide a promising solution to this problem. These
techniques have revealed key neuroanatomical circuits implicated
in core ASD deficits, including networks of brain regions engaged
in social reward/social motivation6 (for example, social orienting,
seeking and enjoying social engagements, and maintaining social
contact), social attention and action observation7,8 (for example,
goal-directed eye-gaze following), and social perception9,10
(for example, face recognition, action perception, emotion
decoding). Here, using a well-validated biological motion func-
tional magnetic resonance imaging (fMRI) paradigm11 that
robustly engages the neural circuits supporting social motivation
and social information processing, we sought to identify predic-
tion/stratification biomarkers that can accurately forecast the
response to an evidence-based behavioral treatment—pivotal
response treatment2 (PRT)—in young children with ASD.
We investigated the accuracy of fMRI neurobiomarkers in
predicting treatment response in a sample (N= 20; 7 girls, 13 boys)
of young (mean age= 5.90 years, s.d. = 1.07 years), cognitively able
(mean IQ= 103.45, s.d. = 17.03) children with ASD. These children
participated in a 16-week trial of PRT, a behavioral treatment
focused on social communication skill development.2,12 The
treatment, PRT, is one of a very few evidence-based treatments
for children with ASD. It targets pivotal areas, including social
initiation and social responsivity with the premise that improve-
ments in these areas lead to more widespread and generalized
improvements in multiple domains of development representing
core changes in social motivation.2,12 PRT consisted of 16 weeks of
treatment, 7 h per week including 5 h per week of direct
intervention with the child and 2 h per week of parent guidance.
The primary clinical outcome measure was the total raw score
from the Social Responsiveness Scale (SRS),13,14 a parent report
measure of social functioning. Treatment effectiveness was
modeled as the delta change scores (that is, post minus pre) of
the SRS total raw scores.
Social orienting and visual sensitivity to biological motion
are evolutionarily well conserved, reflecting an ontogenetically
early-emerging mechanism, fundamental to adaptive social
engagement.10,15–18 We targeted neuroanatomical networks
involved in social motivation and social information processing
via a well-validated point-light display biological motion
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paradigm. During a 5 min fMRI scan at 3 Tesla, conducted at
baseline within 1 week before PRT treatment, our study
participants viewed neuroimaging stimuli depicting point-light
displays of coherent biological (BIO) or scrambled biological
(SCRAM) motion, created from motion capture data (that is, videos
created by placing lights on the major joints of a person and
filming them moving in the dark).11,19
Although relatively impoverished stimuli, point-light displays
contain sufficient information to identify the kind of motion being
produced (for example, walking, dancing, reaching), as well as the
identity of the agent.20 Unique sensitivity to point-light displays is
present across species and early in postnatal development. For
instance, newly hatched chicks recognize biological motion in
point-light displays,15 and 2-day-old human infants preferentially
attend to biological motion in point-light displays.16 Importantly,
in a group of 2-year-old children with ASD, Klin et al.19
documented a failure to orient preferentially toward point-light
displays of canonical biological motion. Elsewhere, disrupted
perceptual sensitivity to biological motion has been documented
in older children with ASD.21 Our prior neuroimaging work
identified dysfunction in the biological motion processing system
as reflecting key neural signatures of ASD in affected children and
as a neuroendophenotype of genetic risk in unaffected siblings of
children with ASD.11 Through our biological motion task, the
present report leveraged these prior discoveries, targeting the
neural systems involved in social motivation and social informa-
tion processing.
MATERIALS AND METHODS
Participants
The study participants included 20 children with a primary diagnosis of
ASD (mean age= 5.90 years, s.d. = 1.07; 7 females, 13 males). Cognitive
ability was measured using the DAS-II (Differential Ability Scales-Second
Edition).22 All the participants were cognitively able (IQ⩾ 70; range= 70–
128). All the participants met DSM-51 diagnostic criteria for ASD as
determined by expert clinical judgment. This judgment was supported by
the results of gold-standard diagnostic instruments—the ADI-R (Autism
Diagnostic Interview-Revised)23 and ADOS (Autism Diagnostic Observation
Schedule)24—administered by research-reliable and licensed clinical
psychologists. All the participants were free of psychotropic medication.
No changes in educational placement or major changes in educational
services were reported by the parents while their children were in the
study. Pretreatment clinical behavioral measures included (a) the parent-
reported SRS13,14 as a continuous, quantitative measure of ASD core
symptom severity, (b) the clinician-administered CELF (Clinical Evaluation
of Language Fundamentals)25,26 as a measure of core language ability
(receptive and expressive) and (c) the clinician-administered Vineland-II
(Vineland Adaptive Behavior Scales-Second Edition)27 as a measure of
adaptive behaviors. Comprehensive demographics and characterization
information are provided in Table 1. The study is registered at ClinicalTrials.
gov (ID: NCT01908686).
Inclusion criteria for all the participants included being in good medical
health and being cooperative with testing; exclusion criteria for all the
participants included a history of significant head trauma or serious brain
or psychiatric illness, as well as current use of prescription medications that
may affect cognitive processes under study (see the ClinicalTrials.gov
registry for complete inclusion and exclusion criteria). Two children
(beyond the 20 participants) were screened and did not qualify for the
study based on the above criteria. One child had significant, uncontrolled
seizures, and the other child exhibited very highly disruptive behaviors so
was unable to complete the screening assessments. Two other participants
(beyond the 20 participants) were not included in the analysis because of
missing valid SRS data. All the participants passed MRI safety screening,
including being free of any metal implants and evidence of claustrophobia.
Written informed consent was obtained from each participant's parent(s),
and assent was obtained from each child. The Human Investigations
Committee at the Yale University approved this study.
Primary clinical outcome
Treatment effectiveness is modeled as the delta change scores of the SRS-
parent total raw scores, that is, post minus pre, such that negative
(positive) delta change scores indicate decrease (increase) in the core
autism symptom severity. Treatment effectiveness was normally distrib-
uted, Shapiro–Wilk’s W= 0.96, df= 20, P=0.45, and was uncorrelated with
pretreatment SRS-parent total raw scores, r(18) =− 0.35, P=0.13. To control
for the passage of time, 11 of our participants were randomly assigned to a
waitlist control group, and received treatment only after their 16-week
waitlist period. The levels of ASD symptom severity did not significantly
differ from the waitlist control baseline (−16 weeks; mean= 91.27, s.
d. = 30.42) to the pretreatment baseline (0 weeks; mean= 84.27, s.
d. = 24.06), Δ=− 7.00, s.d. of Δ=15.79, t(10) =− 1.47, P=0.17 (two-sided),
95% confidence interval of Δ= [− 17.61, 3.61], Cohen’s drm
28 = 0.24.
Treatment approach
After the pretreatment scan was performed and the baseline clinical
measures were taken, the participants received 16 weeks of PRT,2,12 which
is a naturalistic, behaviorally based treatment approach. PRT involves
specific treatment components (child choice, child attending, clear
opportunity, contingent reinforcement, natural reinforcement, reinforce-
ment of attempts and interspersed maintenance/acquisition tasks)
designed to increase the child’s social motivation. In addition, PRT is
highly naturalistic. In the context of the current study, the sessions were
play-based, relying on materials such as craft supplies, balls, blocks and
‘play-doh’. For each child, the treatment included a total of 7 h of
treatment per week. The sessions were held in the clinic as well as in the
child’s home. Five hours per week were direct intervention with the child,
and 2 h per week consisted of parent-training sessions. The treatment
targeted pivotal areas, including social initiation and responsivity, with
the premise that improvements in these capacities should lead to
more widespread and generalized improvements in multiple areas of
Table 1. Participants demographics and pretreatment characteristics
Variable Mean (s.d.)
Pretreatment age (years) 5.90 (1.07)
Gender, male (0= f, 1=m) 0.65 (0.49)
General conceptual ability (IQ) 103.45 (17.03)
Handedness, right (1= right, 0= ambi., − 1= left) 0.70 (0.66)
Pretreatment ADOS calibrated severity score 7.65 (2.11)
Pretreatment SRS-parent total raw score 80.65 (22.53)
Pretreatment CELF core standard score 90.40 (23.88)
Pretreatment Vineland-II communication
Receptive 39.60 (19.09)
Expressive 47.45 (13.01)
Written 75.45 (13.35)
Pretreatment Vineland-II daily living skills
Personal 49.50 (13.13)
Domestic 54.05 (22.92)
Community 61.80 (18.26)
Pretreatment Vineland-II socialization
Interpersonal relationships 40.35 (11.99)
Play and leisure time 46.25 (16.93)
Coping skills 41.30 (17.87)
Pretreatment scan, head motion
(mean absolute, mm)
1.32 (1.34)
Pretreatment scan, head motion
(mean relative, mm)
0.44 (0.44)
Abbreviations: ADOS, Autism Diagnostic Observation Schedule; ambi.,
ambidextrous; CELF, Clinical Evaluation of Language Fundamentals; f,
female; IQ, intelligence quotient; m, male; SRS, Social Responsiveness Scale;
Vineland-II, Vineland Adaptive Behavior Scales-Second Edition. Vineland-II
scores were age equivalents in months. Treatment outcome was the
change score of SRS-parent total row score, that is, post minus pre.
Number of participants: gender= 7 f/13 m; handedness= 16 right/2 ambi./
2 left.
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development, representing core changes in social motivation. A more
detailed description of PRT can be found in the original instruction
manual12 and in an updated guide.29 Because the parent-training
component is inherent in our treatment approach, parents were not
blinded to the intervention. Overall, the sample reported here represents
the provision of 2240 h of direct therapeutic intervention (1120 individual
family visits), 20 one and a half hour scanning sessions, and 60 two-hour
clinical evaluations, for a total of 1220 direct interactions (totaling 2390 h)
with our 20 participating ASD families.
All the clinicians involved in the treatment were extensively trained in
PRT. The faculty from the University of California Santa Barbara, the
research institution where PRT was developed, trained the lead clinician
(PV). The lead clinician sent two separate videotaped sessions (of different
children) to the trainer to ensure maintenance of treatment fidelity. Both
videos met the standard fidelity criteria. To ensure that the bachelors-level
clinicians were correctly implementing PRT during their sessions, they met
with the licensed (lead) clinician for 2 h per week. During these meetings,
clinicians discussed the children’s progress, current presentation and
specific activities for the treatment sessions that would be motivating and
foster skill development. In addition, the lead clinician observed sessions
live and via videotape at least once weekly for each participant. Formal
fidelity of implementation was assessed for two randomly coded treatment
sessions for each subject. Two randomly selected 5 min segments
per session were used for this fidelity assessment. The standard
fidelity assessment published by the developers of the approach was
used, and per convention, fidelity was defined as demonstrating the
treatment components (child choice, child attending, clear opportunity,
contingent reinforcement, natural reinforcement, reinforcement of
attempts and interspersal of maintenance/acquisition tasks) in 80% of
opportunities.12,29,30 The scoring was dichotomous; if the therapist
demonstrated the component, a checkmark was used, and if not, a minus
was used. All the therapists maintained the defined treatment fidelity
across the duration of the study.
Imaging task
We measured the pretreatment blood oxygen level dependent (BOLD)
responses using a well-established biological motion fMRI task,11,31 which
was well tolerated by the young children with ASD in our study. We
selected this paradigm to engage the brain regions involved in social
perception, action observation, social cognition and social motivation. We
reasoned these networks would be those most likely to relate to the
targets of PRT. This same kind of task has been used with success in adults
with and without ASD, as well as infant siblings of children with ASD, and
toddlers with and without ASD. Thus, it represents a robust neuroimaging
paradigm to measure the brain responses during social information
processing across the lifespan in ASD. Before the treatment, the
participants were scanned while viewing coherent and scrambled
point-light displays of biological motion created from motion capture
data. The coherent biological motion displays featured an adult male actor
performing movements relevant to early childhood experiences, such as
playing pat-a-cake,19 and contain 16 points corresponding to major joints.
The scrambled motion animations were created by selecting all the 16
points from the biological motion displays and randomly plotting their
trajectories on a black background. Thus, the coherent and scrambled
displays contained the same local motion information, but only the
coherent displays contained the configuration of a person.20 During the
MRI scan, the stimuli were presented using E-Prime 2.0 software
(Psychological Software Tools, Pittsburgh, PA, USA). Six coherent biological
motion clips (BIO) and six SCRAM motion clips were presented (see
Supplementary Figure 1) once each in an alternating-block design (time
per block, ~ 24 s). The experiment began with a 20 s fixation period and
ended with a 16 s fixation period. The total duration was 328 s. The movies
were presented without audio. The participants were asked to watch the
videos and reminded to remain still and alert. Compliance with this request
was facilitated via a mock scan before the actual scan and ensured by post-
scan interview. All the children complied with this request. The imaging
task and stimuli are available from the authors upon request.
Imaging acquisition and processing
The scanning was performed on a Siemens MAGNETOM 3 Tesla Tim Trio
scanner at the Yale Magnetic Resonance Research Center. For each
participant, a structural MRI image series was acquired with a 32-channel
head coil, a T1-weighted MPRAGE sequence, and the following parameters:
160 sagittal slices; repetition time (TR) = 1900 ms; echo time (TE) = 2.96 ms;
flip angle = 9°; slice thickness = 1.00 mm; voxel size = 1 × 1× 1 mm3;
matrix = 256× 256; and field of view= 256× 256 mm2. Afterwards, BOLD
T2*-weighted functional MRI images were acquired using the following
parameters: 164 volumes; TR = 2000 ms; TE = 25 ms; flip angle = 60°; slice
thickness = 4.00 mm; voxel size = 3.44 × 3.44 × 4.00 mm3; matrix = 64 × 64;
field of view= 220× 200 mm2; number of slices per volume= 34; and
interleaved acquisition.
The T1-weighted MPRAGE structural scan was segmented by SPM12 into
gray matter, white matter and cerebrospinal fluid images. This method is
highly accurate and has reduced bias relative to manual measurement.32
The fMRI data were processed using FSL33 v5.0.8 and the participant-
level preprocessing steps followed a standardized processing stream—ICA-
AROMA (ICA-based strategy for Automatic Removal of Motion Artifacts).34
This consisted of the following sequence: (a) motion correction using
MCFLIRT; (b) interleaved slice timing correction; (c) BET brain extraction; (d)
grand mean intensity normalization for the whole four-dimensional data
set; (e) spatial smoothing with 5 mm full width at half maximum; (f) data
de-noising with ICA-AROMA,34 which uses a robust set of theoretically
motivated temporal and spatial features to remove motion-related
spurious noise; (g) nuisance regression using time series for white matter
and cerebrospinal fluid signal to remove residual, physiological noise; and
finally (h) high-pass temporal filtering (100 s). The first 4 s were discarded
to establish T1 equilibrium. Registration of the fMRI data was performed
using both the subject’s structural scan and then the Montreal
Neurological Institute (MNI152) standard brain. Preprocessed data were
then pre-whitened using FSL’s FILM to remove time series autocorrelation.
To model the BIO and SCRAM conditions, the timing of the
corresponding blocks was convolved with the default gamma function
(phase= 0 s, s.d. = 3 s, mean lag = 6 s) with temporal derivatives. The
participant-level contrast of interest is BIO4SCRAM, which served as inputs
for the subsequent mass univariate, whole-brain, group-level general linear
model (GLM) analyses and multivariate pattern analyses. Sex was controlled
for as a covariate of no interest across all group-level analyses. The main
findings remained largely the same when sex was not controlled for in the
analyses. The data sets during and/or analyzed during the current study are
available from the corresponding author on reasonable request.
Mass univariate group-level GLM analyses
We conducted mass univariate voxel-wise GLM analyses across the whole
brain to identify clusters where pretreatment BOLD activation in the
contrast of BIO4SCRAM predicted treatment effectiveness. The analyses
were conducted using mixed-effects modeling with FSL’s FLAME (FMRIB's
Local Analysis of Mixed Effects) 1+2 inference algorithm, with a voxel-level
threshold of Z42.33, Po0.01 and corrected for multiple comparisons at a
cluster-level threshold of Po0.05. Information about the surviving clusters
was reported, including number of voxels in the cluster, the anatomical
regions covered by the clusters based on the Automated Anatomical
Labeling v2 (AAL2) atlas,35 the coordinates of the peak voxels within each
of the anatomical regions and the Z-statistics associated with the peak
voxels.
Meta-analytical reverse inference
To understand the functional relevance of the surviving clusters, we
performed a quantitative reverse inference using NeuroSynth (http://www.
neurosynth.org/). The NeuroSynth data set v0.6 contains activation data for
over 11 406 studies and feature information for over 3300 term-based
features. The term-based features were derived from the abstracts of
articles in the NeuroSynth database. For each feature, the database stores
the whole-brain, reverse inference, meta-analysis map, P(Term | Activation),
that is, the likelihood that a feature term is used in a study given the
presence of reported activation.36 Each surviving cluster was decoded with
NeuroSynth, which computed the voxel-wise Pearson correlation between
the cluster image file and the meta-analytical image file associated with
each of the 3300 feature terms. The top 10 psychological functional terms
(for example, multisensory, reward) with the highest positive correlation
were retained and reported, while we omitted non-functional terms, such
as (but not limited to) those describing an anatomical region (for example,
inferior temporal), a technique/method/task (for example, multivariate
pattern), a population (for example, older adults), a disorder/disability/
impairment (for example, cognitive impairment) or being relatively generic
(for example, scale, weight, periods, emerged and so on).
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Multivariate pattern analyses
To guard against data over-fitting and to gain understanding of how
different voxels in the network of the clusters derived from the mass
univariate GLM analyses worked together in predicting treatment
effectiveness, we utilized regression-based multivariate pattern analyses
(MVPAs).37 In MVPA, the samples were divided into training and testing
data sets, which constitute a cross validation framework in which the
predictive model is first trained with the training set and then used to
predict the regression labels of the sample in the testing set. This type of
cross validation provides approximately unbiased estimates of effects,
generalizable to new samples, helping to minimize the likelihood that the
results over-fit the data. Moreover, in contrast to the mass univariate voxel-
wise GLM analyses, MVPA draws on the multivariate information across
many voxels comprising neural networks, which may capture how the
voxels or regions work together to achieve complex functions. All these
characteristics render MVPA well suited for establishing robust predictive
biomarkers. MVPA has been applied to fMRI data to successfully predict
treatment response or long-term outcome in a number of neuropsychiatric
or neurocognitive disorders, such as depression,38 dyslexia,39 social anxiety
disorder40,41 and panic disorder.42
MVPAs were performed using the Pattern Recognition for Neuroimaging
Toolbox43 (PRoNTo) v2.0 in Matlab and followed several steps. First, each
participant’s pretreatment Z-statistic BIO4SCRAM contrast image (up-
sampled to the standard MNI152 space using trilinear interpolation) was
inputted into the MVPA analyses. The surviving cluster(s) derived from the
univariate analysis as a network was used as an analytical mask. Because
our objective was to predict treatment effectiveness as a continuous
variable, the delta change of ASD symptom severity was entered as the
regression target. Second, PRoNTo computed a linear kernel (that is, dot
product) between the voxel intensities within the mask for each pair of the
input images, thereby generating a 20× 20 similarity matrix, which served
as the input feature set for the subsequent machine learning algorithm.
Third, we used kernel ridge regression44 as the multivariate regression
method. This is the dual-form formulation of ridge regression and solves
regression problems with high dimensional data in a computationally
efficient way. Cross validation was based on a leave-one-subject-out
(LOSO) framework with mean-centered features across training images. We
selected LOSO (which is equal to 20-fold cross validation with our sample)
because a larger number of folds may reduce bias of the estimates, even at
the cost of increasing variance of the estimates, and should provide more
accurate estimates of neural predictability, especially when sample sizes
are small. For each fold, one input image was left out and served as the
testing set. The kernel ridge regression machines were trained to associate
treatment effectiveness with the multivariate information in the remaining
sample of 19 participants. The trained kernel ridge regression machines
were then used to predict treatment effectiveness in the left-out image.
This step was repeated for each of the 20 folds. Across all folds, predictive
accuracy was calculated as the Pearson’s correlation coefficient (r),
coefficient of determination (R2), and normalized mean squared error
(nMSE) between predicted and actual treatment effectiveness. Fourth, the
significance of the prediction accuracy statistics was evaluated using a
permutation test, consisting of 50 000 iterations. In each iteration, the
regression targets were randomly permuted across all the participants
and the cross-validation procedure was repeated. The P-values of r, R2
and nMSE were then calculated as the proportion of all permutations
where r, R2 and nMSE were greater than (or less than, in the case of nMSE)
or equal to the obtained r, R2 and nMSE, respectively.
RESULTS
Primary clinical outcome
Comprehensive demographics and characterization information
are provided in Table 1. As illustrated in Figure 1, PRT significantly
reduced core ASD symptom severity in terms of parent-reported
SRS total raw scores from pretreatment (mean= 80.65, s.d. = 22.53)
to posttreatment (mean= 65.85, s.d. = 23.09), Δ=− 14.80, s.d. of
Δ= 17.14, t(19) =− 3.86, P= 0.001 (two-tailed), 95% confidence
interval of Δ= [− 22.82, − 6.78], Cohen’s drm
28 = 0.65 (medium to
large).
Mass univariate GLM analyses
As illustrated in Figure 2, the whole-brain mass univariate GLM
analyses of the pretreatment brain BOLD response to BIO vs
SCRAM on the change in SRS total raw score from baseline to
treatment end point revealed four distinct clusters of neuropre-
dictive activities. Cluster 1 (359 voxels) contained a set of right-
hemisphere brain areas involved in social perception: the fusiform
gyrus, inferior temporal gyrus and middle temporal gyrus
extending into the posterior superior temporal sulcus region.9,10
Cluster 2 (403 voxels) included a set of right-hemisphere brain
regions, part of the well-known social attention network7 and
dorsal attention network,45–47 implicated in goal-directed (top-
down) shifts in attention (for example, following gaze directions of
others) and action observation8 and including (but not limited to)
the inferior parietal gyrus and superior parietal lobule. Cluster 3
(534 voxels) included a set of right-hemisphere brain regions, well
known for their role in the experience and regulation of
emotion,48 as well as for coding the reward value of external
stimuli:49 orbitofrontal cortex, ventrolateral prefrontal cortex,
anterior insula and temporal pole. Finally, Cluster 4 (888 voxels)
encompassed a set of left-hemisphere neuroanatomical structures
commonly implicated in social memory and social motivation/
social reward: putamen, pallidum, amygdala, hippocampus and
ventral striatum.6,50 Figure 2 also demonstrates the form of the
neuropredictive relationship with a scatterplot of the change in
core ASD symptom severity (y axis) vs pretreatment BIO4SCRAM
activity (x axis) for each of the four clusters. As can be seen, greater
levels of pretreatment activation in these circuits were negatively
correlated with changes in severity brought about by PRT, such
that greater pretreatment activation was associated with greater
reduction in severity. There was no region that showed positive
correlations between pretreatment activation and changes in
severity. Supplementary Table 1 lists the peak significance, spatial
extent and anatomical locations encompassed by each predictive
cluster.
We conducted a NeuroSynth-based (http://neurosynth.org)
reverse inference analysis to further interpret the possible
functions of the neuropredictive clusters. As illustrated in
Supplementary Table 2, Cluster 1 correlates with multisensory
and cross modal perception, response selection, object perception
and motion perception. Cluster 2 correlates with numerical
processing (which is one of functions of the intraparietal
Figure 1. Treatment effectiveness quantified as the change in SRS
total raw score. Left: the black lines indicate each child’s change in
core autism symptom severity from pretreatment to posttreatment;
the red line is the group mean. Right: the mean and the 95%
confidence interval (CI) of Δ, the change score (that is, post minus
pre). SRS, Social Responsiveness Scale.
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cortex,51 besides social attention) and visuospatial attention.
Cluster 3 correlates with constructs including response inhibition
and emotion regulation. Finally, Cluster 4 correlates with the
constructs of reward and motivation (for example, sexual,
reward, unpleasant, pleasant, motivation). The image files from
this analysis are available at http://neurovault.org/collections/
1551/ so that interested readers may independently decode the
image files with NeuroSynth through links within the NeuroVault
website.
Multivariate pattern analyses with cross validation
To guard against the possibility of data over-fitting in the mass
univariate analysis, and to gain an understanding of how the
voxels comprising the univariate clusters work together in
predicting treatment effectiveness, we applied regression-based
MVPA of pretreatment BOLD responses to the contrast of
BIO4SCRAM with LOSO cross validation in the voxels comprising
the four univariate clusters. As shown in Table 2, the neuropre-
dictive network consisting of the four clusters survived cross
Figure 2. Prediction of treatment effectiveness using univariate general linear model (GLM). Four distinct brain regions, in which greater
pretreatment BOLD activation (% signal change) in the contrast of biological vs scrambled motion was associated with greater treatment
effectiveness. Scatterplot illustrating pretreatment BOLD activation and actual change in severity (that is, post minus pre), with a horizontal
reference line at y= 0 indicating no change from pretreatment to posttreatment (that is, post=pre). BOLD, blood oxygen level dependent;
FFG, fusiform gyrus; OFC, orbital frontal cortex; pSTS, posterior superior temporal sulcus; R, right; SPL, superior parietal lobule; TP,
temporal pole.
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validation—the multivariate pattern information from this brain
network significantly predicted treatment outcome (r= 0.85,
Po0.0001; R2 = 0.72, P= 0.0001; nMSE= 1.33, Po0.0001).
Figure 3 (top) shows the weight map (that is, model parameters)
in the representative slices of this network derived from the
multivariate modeling of pretreatment images predicting treat-
ment response. Figure 3 (bottom) shows the scatter plot of actual
vs predicted treatment response. Each of the points in this plot
was derived from a separate training set, whereas for a new
unseen child (testing set), the remaining participants’ data were
used as the training set. Thus, the correlation is not a standard
correlation derived from a single set of participants. Rather, each
point reflects different combinations of training and testing sets.
We also conducted MVPA analyses with a comparison/control
region of interest that we did not expect to be predictive of
treatment outcome. The inferior occipital gyrus was selected
because (i) it is roughly the same size as the neuropredictive
network, yet it does not overlap with the neuropredictive network,
(ii) it responds strongly to a range of visual stimuli including the
SCRAM and BIO stimuli used here and (iii) it was shown to be
neuropredictive of treatment effectiveness in a markedly different
neuropsychiatric condition, social anxiety disorder.1,52 Further-
more, we conducted MVPA with the whole brain (including the
neuropredictive network) to evaluate the specificity of our
findings to the network of these four univariate clusters. As
shown in Table 2, neither the comparison region of interest nor
the whole-brain analysis was predictive of treatment outcome (P-
values 40.05).
Demographic and behavioral findings
To evaluate whether fMRI provides unique information concerning
the prediction of response to PRT, we examined how a host of
demographic and pretreatment clinical behavioral measures
predict treatment outcome. We ran correlation analyses between
each of the measures listed in Table 1 and the delta changes in
SRS total raw scores. No measure showed a significant correlation,
P-values 40.05.
DISCUSSION
Among young, cognitively able boys and girls with ASD, we
discovered a brain network in which the pretreatment brain
activities engaged during biological motion viewing predict
treatment response to an evidence-based behavioral intervention.
Specifically, the network includes key brain regions supporting
social information processing (the superior temporal sulcus region,
fusiform gyrus, superior parietal lobule) and social motivation
(orbitofrontal cortex, putamen, ventral striatum). Critically, the
results were supported by MVPA, which utilized a standard cross
validation framework, suggesting that the patterns of brain
activities across these brain regions may serve as robust predictive
biomarkers, generalizable to new, unseen participants.
To our knowledge, the current findings provide the first clear
evidence of a neuroimaging-informed stratification/predictive
biomarker in ASD. Our findings move the field toward the goal
of targeted, personalized treatment for individuals with ASD. The
knowledge gained can be utilized in future work to tailor
individualized treatment, refine PRT and develop novel interven-
tions. This study adds to the understanding of the pretreatment
Table 2. Predictive accuracy of the univariate neuropredictive clusters, as estimated by MVPA with cross validation
Mask Nvoxels r P(r) R
2 P(R2) nMSE P(nMSE)
Univariate neuropredictive network 2184 0.85 o0.0001 0.72 0.0001 1.33 o0.0001
Inferior occipital gyrus 1930 −0.14 0.62 0.02 0.66 6.89 0.39
Whole brain 228 453 0.16 0.17 0.02 0.67 4.63 0.15
Abbreviation: MVPA, multivariate pattern analysis. Prediction accuracy was indicated by Pearson’s correlation coefficient (r), coefficient of determination (R2)
and normalized mean squared error (nMSE) between predicted and actual treatment effectiveness. Significance (P-value) was determined with a random
permutation test (50 000 iterations). Significant regions and statistics were displayed in bold. Cross validation was based on a leave-one-subject-out
framework.
Figure 3. Predictive accuracy of the univariate neuropredictive
clusters, as estimated by MVPA with cross validation. Top: weight
map showing the relative weights derived from the multivariate
modeling of pretreatment response to biological motion that
contributed to the prediction of change in severity (that is, post
minus pre) at representative slices (MNI152 mm space). Bottom:
scatterplot illustrating actual and predicted treatment effectiveness,
with a horizontal reference line at y= 0 indicating no change from
pretreatment to posttreatment (that is, post=pre). Cross validation
was based on a leave-one-subject-out framework. MNI, Montreal
Neurological Institute; MVPA, multivariate pattern analysis; R, right.
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neural underpinnings of successful behavioral response to PRT. In
the future, our results may drive the construction of algorithms to
predict which, among several treatments, is most likely to benefit
a given person. In addition, PRT is a multi-component treatment;
hence future studies might use dismantling designs to isolate
treatment components and their association with the neuropre-
dictive targets identified here. This line of work could inform the
development of treatment strategies that would target specific
patterns of neural strengths and vulnerabilities within a given
patient—consistent with the priority of creating individually
tailored interventions, customized to the characteristics of a given
person.
The predictive biomarkers identified in this paper can be
interpreted as the pretreatment neurobiological readiness to
respond to a specific treatment, PRT. It should be noted that the
brain regions where activity before treatment correlated with SRS
scores before treatment (see Supplementary Table 3) did not
overlap with the neuropredictive network described here, which
indicates that the neuropredictive network is specific to change in
severity in young children with ASD. As such, our findings offer the
hope that pre- or concurrent-treatments (whether pharmacologi-
cal, direct stimulation, neurofeedback, or behaviorally based) that
improve the functioning of the neuropredictive markers identified
here, may increase the effectiveness of evidenced-based beha-
vioral treatments for core deficits in children with ASD. On the
other hand, our findings are also particularly important for those
children who would otherwise be the least likely to benefit from
these expensive and time-consuming forms of treatment. For
example, in a randomized, double-blind, cross-over functional
fMRI study,53 we reported that intranasal oxytocin administered to
children with ASD increases activity during social vs nonsocial
judgments in several of the same brain regions identified as
predictive in the present study (for example, amygdala, orbito-
frontal cortex, superior temporal sulcus region and ventral
striatum). These findings, coupled with those in the current
report, raise the provocative hypothesis that the administration of
intranasal oxytocin, by priming key neural circuits for social
motivation and social perception, may serve to enhance the
effectiveness of interventions like PRT in the very children who
might be less biologically ready to respond.
Limitations
There are several limitations that should be considered regarding
this research. First, while our research is the first to identity
neuropredictive biomarkers in the field of ASD and we did not
have sufficient information regarding established effect sizes that
would allow us to pre-determine the required sample size, the
overall sample size (n= 20) is relatively small, although a power
analysis utilizing G*Power54 indicated that it is sufficiently
powered (β= 0.80) to detect a large size of effect55 (|r|⩾ 0.50,
one-sided; in this research, r refers to the correlation between
pretreatment brain activation level and treatment effectiveness).
Future research should use a larger sample to detect small-to-
medium sizes of effect. Second, the primary clinical outcome is the
delta change score of the parent-reported SRS total raw score, and
given that the parent training is inherent in the treatment
approach, the parents were not (and could not be) blinded to the
intervention. As such, there is a need for future research to include
measures that are more objective and/or filled out by blinded
clinician(s), which would provide a more comprehensive picture of
treatment outcome, although the parent-reported SRS total raw
score is one of a very few measures that could provide continuous
quantification of symptom severity in ASD in naturalistic settings.
Third, our neuropredictive findings were limited to one single
treatment-only group in a pretest–posttest design, and future
work should conduct randomized controlled trials to further
establish these findings. Finally, although MVPA with LOSO cross
validation provides supporting evidence that our univariate
biomarkers may generalize to new, unseen samples, the results
are nonetheless limited to the current data and thus the
generalizability should be further tested in an independent
sample beyond the current data.
CONCLUSIONS
Early childhood provides an important window of opportunity for
intervention in ASD. The promise of targeted, individualized,
precision treatment for core deficits in ASD depends on sensitive,
objective biomarkers that can predict how individual young
children with ASD will respond to specific treatment(s). For the
first time in the field of ASD, we provide evidence that neural
signatures in brain circuits implicated in social information
processing and social motivation/reward can predict treatment
effectiveness at the individual level in young boys and girls with
ASD. The results open a new avenue for important future research
and should greatly accelerate progress toward more precise and
effective treatments for core deficits in ASD.
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